CRO BioPharma Services hands over early-stage facility for COVID-19 research

Coronavirus Subway Train
BioPharma Services says it is donating staffers and clinical resources as the coronavirus spreads more rapidly outside of the China epicenter. (David Paul Morris/Bloomberg via Getty Images)

With the first deaths being registered in North America this week, contract research organization BioPharma Services says it is donating staffers and clinical resources to help fight the disease.

The Toronto-based company said in a statement that it has “decided to donate its World Health Organization (WHO) approved facility for coronavirus COVID-19 vaccine research and treatments.”

It said as part of this, it invites all biotech companies working on a vaccine to come talk to BioPharma to see how they can help.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: CROs, clinical researchers brace for impact of coronavirus shutdown across China

Fathi Abuzgaya, M.D., chairman of the board at BioPharma Services, said: “The race is on to shorten the development time of a COVID-19 vaccine. This coronavirus has not yet been categorized as a pandemic but based on what we have learned from SARS, the potential is real. The team here stands ready today to use our early stage medical research capabilities to support the development of a much-needed vaccine.”

Renzo DiCarlo, CEO, added: “We are very proud today to offer our Phase I services to assist the global community. We have been an active partner with the USFDA to further drug research and we are well prepared to do the same for this current global need.”

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.